四环医药(00460.HK)治疗急性缺血性脑卒药品临床研究成果发表
四环医药(00460.HK)公布,集团完成的Cinepazide Maleate注射液(克林澳)治疗急性缺血性脑卒中的上市後确证临床研究之主要研究成果,日前发表於英国BMC期刊集团旗下的神经科专刊杂志BMC Neurology。
集团指,研究成果的成功发表,使药品成为截至目前国内脑卒中领域内,继第一个成功完成上市後大型随机对照试验(RCT)确证性研究之後,又领先在国际SCI期刊发表其有效改善脑卒中患者预後,减少致残率的治疗急性缺血性脑卒中药品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.